

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/560,807-Conf. #9005	
			Filing Date	April 25, 2006	
			First Named Inventor	Marc PORT	
			Art Unit	1618	
			Examiner Name	L. H. Schlientz	
Sheet	1	of	2	Attorney Docket Number	3493-0156PUS1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ² -Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁴
	BA	WO-0160820-A2	08-23-2001	Du Pont Pharm Co		
	BB	WO-9641647-A1	12-27-1996	Barnes Jewish Hospital D B A		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. ¹ Include copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ³ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO <h2 style="text-align: center; margin: 10px 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; margin: 10px 0;"><i>(Use as many sheets as necessary)</i></p>		<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th colspan="2" style="text-align: center; font-weight: normal;">Complete if Known</th> </tr> <tr> <td style="width: 30%;">Application Number</td> <td>10/560,807-Conf. #9005</td> </tr> <tr> <td>Filing Date</td> <td>April 25, 2006</td> </tr> <tr> <td>First Named Inventor</td> <td>Marc PORT</td> </tr> <tr> <td>Art Unit</td> <td>1618</td> </tr> <tr> <td>Examiner Name</td> <td>L. H. Schlientz</td> </tr> <tr> <td>Attorney Docket Number</td> <td>3493-0156PUS1</td> </tr> </table>		Complete if Known		Application Number	10/560,807-Conf. #9005	Filing Date	April 25, 2006	First Named Inventor	Marc PORT	Art Unit	1618	Examiner Name	L. H. Schlientz	Attorney Docket Number	3493-0156PUS1
Complete if Known																	
Application Number	10/560,807-Conf. #9005																
Filing Date	April 25, 2006																
First Named Inventor	Marc PORT																
Art Unit	1618																
Examiner Name	L. H. Schlientz																
Attorney Docket Number	3493-0156PUS1																
Sheet	2	of	2														

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	LANCELOT, Eric et al., "Evaluation of matrix metalloproteinases in arteriosclerosis using a novel noninvasive imaging approach", Arteriosclerosis, Thrombosis, and Vascular Biology, March 2008, Vol. 28, pp. 425-432.	
	CB	ODAKE, Shinjiro et al., "Inhibition of matrix metalloproteinases by peptidyl hydroxamic acids", Biochemical and Biophysical Research Communications, March 30, 1994, Vol. 199, No. 3, pp. 1442-1446.	
	CC	GREENWALD, Robert A., "Thirty-six years in the clinic without an MMP inhibitor", Annals New York Academy Of Sciences, 1999, Vol. 878, pp. 413-418.	
	CD	LEUNG, Kam, "Gadolinium-1,4,7,10-tetraazacyclododecane-N',N'',N''', N'''- tetraacetic acid-Gly-Pro-D-Ala-NHOH", MICAD (NIH Molecular Imaging & Contrast Agent Database), December 15, 2008.	
	CE	GORODIN, P. et al., "Noninvasive diagnosis of matrix metalloproteinase expression in experimental atherosclerotic plaques and its downregulation by dietary modification", The Journal of Nuclear Medicine, Proceedings of the SNM 49th Annual Meeting, June 16, 2002, p. 2.	
	CF	SCHAEFERS, M. A. et al., "A new successful approach of imaging vulnerable arteriosclerotic plaque in vivo using a radiolabelled MMP inhibitor", The Journal of Nuclear Medicine, Proceedings of the SNM 50th Annual Meeting, June 2003, p. 192.	
	CG	WEINREB D.B. et al., "In vivo imaging of matrix metalloproteinase activity with P947-enhanced MRI in atherosclerotic plaques of hypercholesterolemic rabbits", Program and abstracts of the Radiological Society of North America 92nd Scientific Assembly and Annual Meeting, November 26-December 1, 2006, Chicago, Illinois, p. 488.	

Examiner Signature	Date Considered	
--------------------	-----------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached